Related Experiment Video
Updated: Mar 31, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Evolving and investigational therapies for benign prostatic hyperplasia
Shiva Madhwan Nair1, Marie Adrianne Pimentel, Peter J Gilling
1Department of Urology, Tauranga Public Hospital, Tauranga, New Zealand.
New surgical techniques for benign prostatic hyperplasia (BPH) offer safer and effective alternatives to traditional methods. Emerging treatments like intra-prostatic injections and thermal therapies show promise for managing lower urinary tract symptoms (LUTS).
Area of Science:
- Urology
- Minimally Invasive Surgery
Background:
- Lower urinary tract symptoms (LUTS) are prevalent, frequently linked to benign prostatic hyperplasia (BPH).
- Conventional surgical interventions like open enucleation and transurethral resection of the prostate (TURP) are effective but carry risks and are operator-dependent.
- This review examines novel surgical approaches for BPH management.
Purpose of the Study:
- To review emerging surgical techniques for benign prostatic hyperplasia (BPH).
- To assess the safety and efficacy of new BPH treatment modalities.
Main Methods:
- A systematic literature search was conducted across major databases including SCOPUS, MEDLINE, EMBASE, and Cochrane.
- Keywords related to BPH and surgical techniques were utilized for comprehensive data retrieval.
Main Results:
- Intra-prostatic injections (NX-1207, PRX-302) demonstrate good safety and early efficacy.
- Thermal therapies (Rezum) and Aquablation show promise as outpatient or automated procedures with favorable safety profiles.
- Prostate artery embolization shows variable outcomes, and histotripsy is still in early feasibility stages.
Conclusions:
- Several new BPH techniques exhibit promising safety and efficacy.
- Further validation through phase III studies is required for widespread adoption.
More Related Videos
06:04Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
Published on: March 6, 2018
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: